Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials. The candidate in question, an oral p300/CBP inhibitor dubbed inobrodib, is currently undergoing a phase 2a study in combination with dexamethasone and Bristol Myers Squibb’s Imnovid for relapsed or refractory multiple myeloma. Source: Fierce Biotech 19/5/2025